These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 15864219)
21. Three-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital-(RESEARCH) registry. García-García HM; Daemen J; Kukreja N; Tanimoto S; van Mieghem CA; van der Ent M; van Domburg RT; Serruys PW Catheter Cardiovasc Interv; 2007 Nov; 70(5):635-9. PubMed ID: 17960629 [TBL] [Abstract][Full Text] [Related]
22. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Schofer J; Schlüter M; Gershlick AH; Wijns W; Garcia E; Schampaert E; Breithardt G; Lancet; 2003 Oct; 362(9390):1093-9. PubMed ID: 14550694 [TBL] [Abstract][Full Text] [Related]
23. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Fajadet J; Wijns W; Laarman GJ; Kuck KH; Ormiston J; Münzel T; Popma JJ; Fitzgerald PJ; Bonan R; Kuntz RE; Minerva Cardioangiol; 2007 Feb; 55(1):1-18. PubMed ID: 17287679 [TBL] [Abstract][Full Text] [Related]
24. Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). Thuesen L; Kelbaek H; Kløvgaard L; Helqvist S; Jørgensen E; Aljabbari S; Krusell LR; Jensen GV; Bøtker HE; Saunamäki K; Lassen JF; van Weert A; Am Heart J; 2006 Dec; 152(6):1140-5. PubMed ID: 17161067 [TBL] [Abstract][Full Text] [Related]
25. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Van den Branden F; Van Langenhove G; J Am Coll Cardiol; 2007 Jul; 50(3):261-7. PubMed ID: 17631219 [TBL] [Abstract][Full Text] [Related]
26. Impact of sirolimus-eluting stent on the outcome of patients with chronic total occlusions. Nakamura S; Muthusamy TS; Bae JH; Cahyadi YH; Udayachalerm W; Tresukosol D Am J Cardiol; 2005 Jan; 95(2):161-6. PubMed ID: 15642545 [TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial. Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB; Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649 [TBL] [Abstract][Full Text] [Related]
33. Sirolimus-eluting stents for the prevention of restenosis in a worst-case scenario of diffuse and recurrent in-stent restenosis. Werner GS; Emig U; Krack A; Schwarz G; Figulla HR Catheter Cardiovasc Interv; 2004 Nov; 63(3):259-64. PubMed ID: 15505841 [TBL] [Abstract][Full Text] [Related]
34. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R; JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414 [TBL] [Abstract][Full Text] [Related]
35. Primary stenting of occluded native coronary arteries: final results of the Primary Stenting of Occluded Native Coronary Arteries (PRISON) study. Rahel BM; Suttorp MJ; Laarman GJ; Kiemeneij F; Bal ET; Rensing BJ; Ernst SM; ten Berg JM; Kelder JC; Plokker HW Am Heart J; 2004 May; 147(5):e22. PubMed ID: 15131557 [TBL] [Abstract][Full Text] [Related]
36. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries). Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443 [TBL] [Abstract][Full Text] [Related]
37. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178 [TBL] [Abstract][Full Text] [Related]
38. Management of distal/bifurcation left main restenosis after drug eluting stents implantation: single center experience. Rigatelli G; Cardaioli P; Dell'Avvocata F; Giordan M; Vassilev D; Fraccaro C; Roncon L; Faggian G Cardiovasc Revasc Med; 2014 Mar; 15(2):76-9. PubMed ID: 24560299 [TBL] [Abstract][Full Text] [Related]
39. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. Rodriguez AE; Granada JF; Rodriguez-Alemparte M; Vigo CF; Delgado J; Fernandez-Pereira C; Pocovi A; Rodriguez-Granillo AM; Schulz D; Raizner AE; Palacios I; O'Neill W; Kaluza GL; Stone G; J Am Coll Cardiol; 2006 Apr; 47(8):1522-9. PubMed ID: 16630986 [TBL] [Abstract][Full Text] [Related]
40. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Colombo A; Moses JW; Morice MC; Ludwig J; Holmes DR; Spanos V; Louvard Y; Desmedt B; Di Mario C; Leon MB Circulation; 2004 Mar; 109(10):1244-9. PubMed ID: 14981005 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]